

OncoTherapy Science, Inc.

FEBRUARY 3, 2014

Announcement of the commencement of patient enrollment in Phase II clinical study of
cancer peptide vaccine S-588410 by Shionogi&Co., Ltd.

OncoTherapy Science, Inc. (President & CEO: Takuya Tsunoda; hereinafter, "OncoTherapy") announces that the patient enrollment in the Phase II clinical study of cancer peptide vaccine S-588410, which contains five oncoantigen peptides and outlicensed to Shionogi&Co., Ltd. (Head office: Chuo-ku, Osaka, President and CEO: Isao Teshirogi, hereinafter "Shionogi"), in bladder cancer patients has been commenced in Japan and Europe, as released by Shionogi today.

This clinical study is to evaluate the clinical effect of S-588410 when administered to the bladder cancer patients.

S-588410 is a mixed peptide cocktail vaccine of S-288310, for which Shionogi has already conducted a clinical study, and S-488310, and is expected to have an advanced efficacy.

OncoTherapy has decided to leave fiscal 2013 full-year forecasts announced on 31th January, 2014 unchanged.